Abstract: Electrospun scaffolds crosslinked with acrylates and methods of making the same are provided. Because the cross-linking linking is carried out under mild conditions, biologically active agents are incorporated into the scaffolds in a facile manner.

Abstract: Electrospun materials are fabricated using air-flow impedance technology, which results in the production of scaffolds in which some regions are dense with low porosity and others regions are less dense and more porous. The dense regions provide structural support for the scaffold while the porous regions permit entry of cells and other materials into the scaffold, e.g. when used for tissue engineering.

Abstract: A method comprising contacting an olefin wax with an oxidizing agent to produce an oxidized olefin wax, contacting the oxidized olefin wax with an odor-reducing material to produce an odor-reduced oxidized olefin wax, and removing water from the odor-reduced oxidized olefin wax. A composition comprising a product of a mixture of an oxidized olefin wax and an odor-reducing material, wherein the needle penetration of the composition is less than the oxidized alpha olefin wax in the absence of the odor-reducing material.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.

Abstract: The present invention discloses processes for producing ?-nitrocarbonyl and ?-dicarbonyl compounds, which can be precursors in the synthesis of pyrrole compounds. A process for producing pyrroles such as 2,5-dimethylpyrrole, and structurally similar pyrrole compounds, is also disclosed.

Abstract: The present invention discloses processes for producing ?-nitrocarbonyl and ?-dicarbonyl compounds, which can be precursors in the synthesis of pyrrole compounds. A process for producing pyrroles such as 2,5-dimethylpyrrole, and structurally similar pyrrole compounds, is also disclosed.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.

Abstract: Photoactivatable dendrimers and hydrogels formed therefrom include dendrimers to which polymer chains (e.g. polyethylene glycol, PEG) have been conjugated; and reactive photoactivatable groups attached to terminal functional groups of the polymer chains (e.g. hydroxyls of PEG). Exposure to a suitable wavelength of light activates the photoactivatable groups, which then crosslink with one another, thereby forming a hydrogel. The hydrogel may also include one or more agents of interest; or, in some embodiments, nanoparticles containing one or more agents of interest may be dispersed in the hydrogel. These formulations are well-suited for sustained or prolonged delivery of active agents, e.g. for the treatment of glaucoma by the sustained delivery of anti-glaucoma agents directly to the eye.

Abstract: This disclosure provides for olefin wax oligomer compositions, methods of producing olefin wax oligomer composition, and methods for oligomerizing olefin waxes. This disclosure encompasses metallocene-based olefin wax oligomerization catalyst systems, including those that include a metallocene and an aluminoxane, a metallocene and a solid oxide chemically-treated with an electron withdrawing anion, and a metallocene, a solid oxide chemically-treated with an electron withdrawing anion, and an organoaluminum compound. The olefin wax oligomers prepared with these catalyst systems can decreased needle penetrations, increased viscosity, and an increased drop melt, making them useful as an additive in candles, stone polishes, liquid polishes, and mold release formulations.

Abstract: The present invention is directed to two novel polymorph form (Form A and Form B) of lapatinib ditosylate, wherein Form A is the hydrate ditosylate salt of lapatinib, and Form B is anhydrate ditosylate salt of lapatinib. The present invention is further directed to amorphous form of lapatinib ditosylate and its solid dispersion. The present invention further provides processes for the preparation of Form A, Form B, Amorphous form and solid dispersion of lapatinib ditosyalte, and a pharmaceutical composition comprising the said forms. Form A and Form B were characterized by X-RPD, DSC, TGA and FT-IR, and can be prepared from recrystallizing lapatinib ditosylate in a mixture of tetrahydrofuran (THF) and water.

Abstract: In one embodiment, we disclose hardened olefin waxes and processes for preparing them. In another embodiment, we disclose oxidized olefin waxes having low viscosity and processes for preparing them. The waxes are suitable for use as polishes, coatings, or inks, among other uses. For example, a hardened olefin wax composition produced from a feedstock olefin wax composition by contacting the feedstock olefin wax composition with an oxygen-containing gas at a temperature greater than a melting point of the feedstock olefin wax composition, the hardened olefin wax composition having: a needle penetration value at 25° C. at least 5 percent less than a needle penetration value at 25° C. of the feedstock olefin wax composition; a a kinematic viscosity at 100° C. of up to about 200% greater than the kinematic viscosity of the feedstock olefin wax composition; and a saponification number less than 5 mg KOH/g hardened olefin wax composition.

Abstract: The present invention discloses processes for producing ?-nitrocarbonyl and ?-dicarbonyl compounds, which can be precursors in the synthesis of pyrrole compounds. A process for producing pyrroles such as 2,5-dimethylpyrrole, and structurally similar pyrrole compounds, is also disclosed.

Abstract: An oxidized olefin wax useful as a pour point depressant for hydrocarbon compositions and/or additive to reduce the wax particle size of wax precipitates in hydrocarbon compositions is described. Method for reducing the pour point and/or wax particle size of hydrocarbon composition with an oxidized olefin wax are described.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.

Abstract: In one embodiment, we disclose hardened olefin waxes and processes for preparing them. In another embodiment, we disclose oxidized olefin waxes having low viscosity and processes for preparing them. The waxes are suitable for use as polishes, coatings, or inks, among other uses.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.

Abstract: A process to oxidize an olefin wax, comprising: contacting a feedstock olefin wax composition with an oxygen-containing gas at a temperature greater than a melting point of the feedstock olefin wax composition melting point, to prepare an oxidized olefin wax composition wherein the oxidized olefin wax composition has an acid number greater than 1 mg KOH/g oxidized olefin wax composition and a kinematic viscosity at 100° C. less than 70 cSt.

Abstract: A method of producing a wax composition having a constrained carbon number distribution and/or a narrow melting range is described. Additionally, hydrocarbon waxes and hydrocarbon wax compositions having a constrained carbon number distribution and/or melting point are described.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.